Nurse Practitioner in Cherry Valley, AR Accepting Medicare
2 Nurse Practitioner nurses found. Showing 1 - 2
 Erin Caldwell, Nurse Practitioner - Pediatrics Medicare: Medicare Enrolled Practice Location: 2624 Highway 42, Cherry Valley, AR 72324 Phone: 870-442-2040 Fax: 870-442-2042 |
Rebecca Powers, APN Nurse Practitioner - Family Medicare: Accepting Medicare Assignments Practice Location: 2624 Highway 42, Cherry Valley, AR 72324 Phone: 870-442-2040 Fax: 870-442-2042 |
News Archive
Long travel distances continue to be an obstacle to breast reconstruction after mastectomy
Long travel distances continue to be a significant obstacle to breast reconstruction after mastectomy for breast cancer, reports a study in the January issue of Plastic and Reconstructive Surgery, the official medical journal of the American Society of Plastic Surgeons.
Study reveals impact of physician financial incentives and highlights importance of patient education
According to a new study by researchers at the Perelman School of Medicine at the University of Pennsylvania, prostate cancer patients of urologists who own expensive radiation equipment are more likely to receive radiation treatment in lieu of surgery than patients treated by urologists without an ownership stake in the equipment.
Why we are unable to distinguish faces of other races (and sometimes our own)
A troubling psychological phenomenon that just about everyone has experienced but few will admit to; having difficulty distinguishing between people of different racial groups.
Cancer-causing fusion protein works by silencing tumor suppressor gene IL-2Rγ
Mariusz A. Wasik, MD, professor of Pathology and Laboratory Medicine, and Qian Zhang, MD, PhD, research assistant professor, both from the Perelman School of Medicine at the University of Pennsylvania, and their colleagues, found that a cancer-causing fusion protein works by silencing the tumor suppressor gene IL-2R common gamma-chain.
RXi Pharmaceuticals to present in vivo data of rxRNA compounds
RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced that it will be presenting new in vivo data on its self-delivering rxRNA compounds at a number of upcoming scientific conferences, detailed below.
› Verified 5 days ago